Skip to main content

NovaBay Pharmaceuticals to Distribute Zocular® Dry Eye Products

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zocular dry eye products alongside Avenova in NovaBay’s physician-dispensed sales channel. Products sold under the Zocular brand were developed by Okra Limited CEO Peter Pham, MD, a board-certified ophthalmologist, and are all complementary to Avenova. They are formulated with Zokrex™, a patented technology with activated natural okra polysaccharide complexes, and are designed to gently and effectively clear Demodex, scurf and residue from eyelids.

“We’ve been searching for additional dry eye products to add to our established sales channels for some time. The Zocular product line is ideal for eyecare specialists seeking effective tools to treat their patients’ dry eye and is a perfect complement to Avenova,” said Justin Hall, NovaBay CEO. “Zocular products are formulated with a novel, powerful technology to address inflammation at the eyelid margin. Avenova is the only lid and lash antimicrobial spray to be clinically proven to reduce the bacterial load on skin surfaces surrounding the eyes, thus addressing the underlying cause of bacterial dry eye. Both Avenova and Zocular at-home products are completely safe for regular use.”

Zocular products include easy-to-use in-office and at-home treatment options. The ZocuKit for ZEST® (Zocular Eyelid System Technology) is a 10-minute, in-office procedure clinically proven to provide dramatic, immediate and lasting results for patients suffering from dry eye. ZEST requires no capital equipment or topical anesthetic, and is well tolerated by patients. At-home consumer dry eye maintenance products include ZocuWipe, a once-daily disposable towel that neutralizes and removes oil, dirt and debris; ZocuFoam, a gentle eyelid cleansing and moisturizing foam; and ZocuShield, an easy-to-apply gel-filled syringe.

“As a dry eye sufferer myself, one of the biggest problems is the time required for any treatment to produce results. We at Okra Limited pioneered the use of natural okra polysaccharides to solve this unmet need – the ability to deliver immediate and durable clinical improvement within minutes to patients with ocular surface problems,” said Dr. Pham. “Linking the Zokrex polysaccharide technology in Zocular products with Avenova’s pharmaceutical-grade hypochlorous acid provides unmatched treatment efficacy for almost any clinical situation. Our team at Okra is delighted to partner with NovaBay to put this powerful combination of products in the hands of eyecare specialists.”

To learn more about Zocular and to order products, eyecare specialists are invited to call 844-ZOCULAR.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on high-quality, differentiated, anti-infective consumer products: Avenova®, the premier antimicrobial lid and lash spray, CelleRx® Clinical Reset™, a breakthrough product in the beauty category, and NeutroPhase® Skin and Wound Cleanser for wound healing. NovaBay’s products are formulated with its patented, pure, stable, pharmaceutical-grade hypochlorous acid that replicates the antimicrobial chemicals used by white blood cells to fight infection. NovaBay’s hypochlorous acid products do not cause stinging or irritation, are non‑toxic and non-sensitizing, making them completely safe for regular use. Avenova is the only commercial hypochlorous acid lid and lash spray product clinically proven to reduce bacterial load on ocular skin surfaces, thus effectively addressing the underlying cause of bacterial dry eye.

NovaBay Pharmaceuticals Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward‑looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current product offerings and marketing efforts, the financial impact of our partnerships, and any future revenue that may result from selling these products, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.


NovaBay Contacts:

At the Company

Justin Hall

Chief Executive Officer and General Counsel



LHA Investor Relations

Jody Cain


Okra LLC Contact:

Peter Pham, MD

Chief Executive Officer


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.